A. Cheng

Jang-Ming Lee, Hsiu‐Po Wang, K. Yeh, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma

M. Kudo, N. Izumi, R. Finn, 2019, Liver Cancer.

Systemic chemotherapy alone for patients with non‐acquired immunodeficiency syndrome‐related central nervous system lymphoma

K. Yeh, A. Cheng, Chiu‐Hwa Wang, 1998, Cancer.

Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence.

Chiun-Sheng Huang, A. Cheng, S. Kuo, 2008, International journal of radiation oncology, biology, physics.

Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

J. Whang‐Peng, Chih-Hsin Yang, Pan‐Chyr Yang, 2005, Oncology.

Combination of 13-cis Retinoic Acid and Interferon-α in the Treatment of Recurrent or Refractory Peripheral T-cell Lymphoma

K. Yeh, Chih-Hung Hsu, A. Cheng, 2002, Leukemia & lymphoma.

Bone marrow involvement in non-Hodgkin's lymphoma.

Y. C. Chen, A. Cheng, H. Lai, 1989, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association.

Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma.

Hsiu‐Po Wang, C. Shun, A. Cheng, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy

Chao-yuan Huang, J. Cheng, A. Cheng, 2014, Acta obstetricia et gynecologica Scandinavica.

Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.

A. Cheng, I. Su, T. Tsai, 1993, Journal of the American Academy of Dermatology.

Cutaneous manifestations of postthymic T cell malignancies: description of five clinicopathologic subtypes.

Y. C. Chen, A. Cheng, I. Su, 1990, Journal of the American Academy of Dermatology.

mucosa-associated lymphoid tissue lymphomas with or without Helicobacter pylori-independent status of low-grade gastric Nuclear expression of BCL10 or nuclear factor kappa B helps predict

K. Yeh, H. Hsu, A. Cheng, 2013 .

Differential response to H. pylori eradication therapy of co‐existing diffuse large B‐cell lymphoma and MALT lymphoma of stomach—significance of tumour cell clonality and BCL10 expression

K. Yeh, H. Hsu, P. Yeh, 2007, The Journal of pathology.

Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21).

K. Yeh, H. Hsu, A. Cheng, 2005, Blood.

Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas.

K. Yeh, H. Hsu, P. Yeh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach.

A. Cheng, I. Chiang, Jaw-Town Lin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

Chih-Hung Hsu, A. Cheng, Chien-Chung Huang, 2012, Clinical Cancer Research.

Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2016, Journal of gastroenterology and hepatology.

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells

A. Cheng, C. Shiau, H-l Chen, 2013, Cell Death and Disease.

Lamivudine and Hepatitis B Reactivation

Pei-Jer Chen, Chiun Hsu, A. Cheng, 2009, Annals of Internal Medicine.

Prognostic Factors in Extrapulmonary Small Cell Carcinomas

A. Cheng, K. Kuo, S. Kuo, 2007, Oncology.

High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country

Jih-Hsiang Lee, Chien-Jen Chen, Chen-Yang Shen, 2015, PloS one.

Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instability.

J. Sheu, C. Shun, A. Cheng, 1997, Cancer letters.

Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers.

C. Shun, K. Yeh, A. Cheng, 1998, Journal of clinical gastroenterology.

afenib Overcomes TRAIL Resistance of Hepatocellular R cinoma Cells through the Inhibition of STAT 3

Feng Chen, Pei-Jer Chen, A. Cheng, 2010 .

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

Kuen-Feng Chen, A. Cheng, C. Shiau, 2010, Clinical Cancer Research.

Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression

Chiun Hsu, A. Cheng, Liang-In Lin, 2015, Clinical Cancer Research.

Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin

Chiun Hsu, A. Cheng, J. Liou, 2014, Molecular Cancer.

Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway

Chiun Hsu, A. Cheng, J. Liou, 2013, PloS one.

Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats.

J. Lin, M. Kuo, S. Chuang, 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Transforming growth factor beta1 attenuates ceramide-induced CPP32/Yama activation and apoptosis in human leukaemic HL-60 cells.

S. Jee, M. Kuo, S. Chuang, 1997, The Biochemical journal.

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

Jih-Hsiang Lee, T. Chen, J. Yang, 2019, Investigational New Drugs.

The B‐cell‐activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa‐associated lymphoid tissue lymphoma without t(11;18)(q21;q21)

M. Wei, C. Shun, K. Yeh, 2016, The Journal of pathology.

A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus.

K. Yeh, Chih-Hung Hsu, P. Yeh, 2006, The Journal of biological chemistry.

13‐cis‐retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki‐1 lymphoma

A. Cheng, J. Chow, I. Su, 1991, Cancer.

Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

P. Gibbs, D. Doval, T. Yau, 2017, Clinical colorectal cancer.

Helicobacter pylori sensitizes TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human gastric epithelial cells through regulation of FLIP

A. Cheng, P. Hsu, P. Hsu, 2014, Cell Death and Disease.

Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance

K. Yeh, A. Cheng, S. Kuo, 2013, Blood Cancer Journal.

Expression of CD86 and increased infiltration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma.

Hsiu‐Po Wang, K. Yeh, H. Hsu, 2005, World journal of gastroenterology.

Medulloblastoma in adults

K. Lan, A. Cheng, S. Kuo, 2012, Strahlentherapie und Onkologie.

Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer

P. Gibbs, R. Lim, A. Cheng, 2019, Asia-Pacific journal of clinical oncology.

Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa.

M. Kuo, P. Yeh, S. Chuang, 2006, The Journal of endocrinology.

ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis

Chih-Hung Hsu, R. Sainson, A. Cheng, 2022, Oncology.

Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells

S. Chuang, A. Cheng, G. Lai, 2016, RNA.

Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study

Chih-Hung Hsu, A. Cheng, Y. Shao, 2022, AntiCancer Research.

Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

Chih-Hung Hsu, C. Yen, A. Cheng, 2022, Hepatology International.

Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan

T. Yau, Chiun Hsu, S. Choo, 2022, Liver Cancer.

ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240

M. Kudo, A. Zhu, R. Finn, 2021, Therapeutic advances in medical oncology.

Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption

A. Cheng, Zhong‐Zhe Lin, C. Chou, 2014, International journal of cancer.

The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2013, Oncology.

Dovitinib, a multiple kinase inhibitor, induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.

Kuen-Feng Chen, A. Cheng, C. Shiau, 2011 .

Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy.

Chih-Hung Hsu, A. Cheng, Y. Shao, 2011, The oncologist.

Targeting histone deacetylase 4/ubiquitin‐conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice

Pei-Jer Chen, J. Cheng, A. Cheng, 2018, Hepatology.

Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy.

C. Shun, K. Yeh, A. Cheng, 1999, Hepato-gastroenterology.

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

L. Jeng, M. Kudo, P. Philip, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report.

Chiun Hsu, K. Yeh, A. Cheng, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC)

Pei-Jer Chen, Chiun Hsu, A. Cheng, 2008 .

Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.

Kuen-Feng Chen, Chao-yuan Huang, A. Cheng, 2013, International Journal of Radiation Oncology, Biology, Physics.

Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides

J. Whang‐Peng, A. Cheng, Li‐Tzong Chen, 2004, Clinical Cancer Research.

Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma

Chiun Hsu, A. Cheng, 2017 .

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Yoon-Koo Kang, Jianming Xu, S. Ye, 2009, The Lancet. Oncology.

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.

M. Kudo, K. Ueshima, R. Lencioni, 2020, Journal of hepatology.

Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases.

M. Ho, Chih-Hung Hsu, A. Cheng, 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters

E. Raymond, S. Faivre, A. Cheng, 2008 .

Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.

J. Neal, A. Cheng, A. Vogel, 2022, Cancer treatment reviews.

Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival

I. Chen, T. Chen, A. Cheng, 2020, Journal of Neuro-Oncology.

A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

A. Cheng, C. Kuo, Ching-Hung Lin, 2015, BMC Cancer.

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.

Kuen-Feng Chen, Pei-Jer Chen, A. Cheng, 2011, Journal of hepatology.

Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.

Kuen-Feng Chen, Pei-Jer Chen, A. Cheng, 2012, Biochemical pharmacology.

1027 Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of signal transducers and activators of transcription 3

A. Cheng, W. Tai, K. F. Chen, 2009 .

Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity.

H. Lien, M. Kuo, P. Yeh, 2006, Lung cancer.

Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

Chih-Hung Hsu, C. Yen, A. Cheng, 2022, Hepatology International.

An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma.

Chih-Hung Hsu, A. Cheng, Y. Shao, 2021, The oncologist.

Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.

Kuen-Feng Chen, Pei-Jer Chen, A. Cheng, 2011, European journal of medicinal chemistry.

Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study

Pei-Jer Chen, Chiun Hsu, A. Cheng, 2014, Hepatology.

A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.

Li-an Xu, A. Cheng, H. Lim, 2014 .

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

J. Furuse, G. Abou-Alfa, R. Kelley, 2014 .

Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.

Chiun Hsu, K. Yeh, A. Cheng, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma

K. Yeh, Chia‐Chi Lin, A. Cheng, 2018, AntiCancer Research.

Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.

A. Cheng, S. Kasper, T. Brodowicz, 2020, European journal of cancer.

Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer

Chiun Hsu, K. Yeh, Chih-Hung Hsu, 2005, Oncology.

Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma

Chih-Hung Hsu, Chia‐Chi Lin, A. Cheng, 2022, Esophagus.

Analysis of the cellular basis of keratinocyte growth factor overexpression in inflammatory bowel disease

P. Finch, A. Cheng, 1999, Gut.

Primary T cell leptomeningeal lymphoma--successful treatment with systemic chemotherapy.

K. Yeh, A. Cheng, H. Tien, 1995, Oncology.

Prognostic factors and predictors of sorafenib beneﬁt in patients with hepatocellular carcinoma: Analysis of two phase III studies

J. Bruix, J. Llovet, A. Cheng, 2017 .

Chiun Hsu, A. Cheng, Pei‐Jer Chen, 2014 .

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

M. Kudo, R. Finn, J. Jassem, 2017 .

Gemcitabine‐based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non‐Hodgkin's lymphoma

A. Cheng, S. Kuo, Shih-Hung Yang, 2009, American journal of hematology.

Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)--possible clinical significance in advanced gastric cancer.

K. Yeh, S. Yeh, A. Cheng, 1998, Anticancer research.

Clinicopathological spectrum of haemophagocytic syndrome in Epstein‐Barr virus‐associated peripheral T‐cell lymphoma

Ming-Tseh Lin, A. Cheng, M. Yao, 1994, British journal of haematology.

Epstein—barr virus‐containing t‐cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis

A. Cheng, L. Weiss, I. Su, 1993, Cancer.

Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2019, Annals of Oncology.

Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

N. Freemantle, G. Abou-Alfa, R. Kelley, 2019, Journal of Clinical Oncology.

Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, T. Yau, A. El-Khoueiry, 2019, Journal of Clinical Oncology.

Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2018 .

Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, A. El-Khoueiry, T. Yau, 2018 .

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

A. Cheng, Y. Kwong, S. Kim, 2012, Leukemia & lymphoma.

Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies.

A. Cheng, I. Su, I. Chang, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma

A. Cheng, H. Hou, Chang-Tsu Yuan, 2022, Virchows Archiv.

Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma

K. Yeh, Chung-Wu Lin, A. Cheng, 2015, The American journal of surgical pathology.

Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling

M. Wei, K. Yeh, A. Cheng, 2021, Cancer cell international.

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

M. Kudo, P. Galle, S. Kaneko, 2019, Journal of Clinical Oncology.

Milestones in the pathogenesis and management of primary liver cancer.

Bruno Sangro, J. Llovet, B. Sangro, 2020, Journal of hepatology.

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

M. Kudo, P. Galle, M. Ducreux, 2019, Annals of Oncology.

Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study.

A. Cheng, I. Su, R. Hong, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristic clinicopathologic features of adult B‐cell lymphoblastic lymphoma with special emphasis on differential diagnosis with an atypical form probably of blastic lymphocytic lymphoma of intermediate differentiation origin

Y. C. Chen, A. Cheng, Yao-chang Chen, 1994, Cancer.

Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone

S. Chuang, A. Cheng, G. Lai, 2006, International journal of cancer.

Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective

Y. Hsueh, A. Cheng, Mei-Hwan Wu, 2005, Cancer Chemotherapy and Pharmacology.

Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.

Y. Pu, A. Cheng, C. Y. Wu, 2001, Anticancer research.

Tamoxifen enhances the chemosensitivity of bladder carcinoma cells.

Y. Pu, A. Cheng, I. Su, 1995, The Journal of urology.

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy

Chih-Hung Hsu, Chia‐Chi Lin, A. Cheng, 2021, Journal of Cancer Research and Clinical Oncology.

BCL10GFP fusion protein as a substrate for analysis of determinants required for Mucosa-Associated Lymphoid Tissue 1 (MALT1)-mediated cleavage

A. Cheng, Ching‐Hwa Tsai, Mei‐Ru Chen, 2012, Journal of Biomedical Science.

Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma

Chung-Wu Lin, A. Cheng, S. Kuo, 2014, Blood Cancer Journal.

Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers

I. Chen, Chiun Hsu, J. Yang, 2014, Supportive Care in Cancer.

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007, The Journal of urology.

High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers

Ming-Tseh Lin, King-Jen Chang, K. Yeh, 1998, Breast Cancer Research and Treatment.

Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells

A. Cheng, Ching‐Hwa Tsai, Mei‐Ru Chen, 2018, PloS one.

Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer

K. Yeh, A. Cheng, Liang-In Lin, 2022, British Journal of Cancer.

Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.

G. Wilding, A. Cheng, P. Hutson, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism.

G. Wilding, A. Cheng, T. Oberley, 1991, Cancer research.

A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.

Chih-Hsin Yang, Chiun Hsu, K. Yeh, 2002, Anticancer research.

A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.

Ming-Tseh Lin, Po-Huang Lee, K. Yeh, 1997, Anticancer research.

Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition.

K. Yeh, A. Cheng, Y. C. Chen, 1997, Oncology.

Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer.

Chiun-Sheng Huang, A. Cheng, S. Kuo, 2000, Anticancer research.

Hepatitis B Virus X Protein Activates a Survival Signaling by Linking Src to Phosphatidylinositol 3-Kinase*

M. Kuo, S. Chuang, A. Cheng, 2003, Journal of Biological Chemistry.

Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma

A. Cheng, S. Kuo, Shih-Hung Yang, 2012, Annals of Hematology.

Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma

Y. Jeng, H. Hsu, Chiun Hsu, 2021, Cells.

5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply

K. Yeh, A. Cheng, 1998, British Journal of Cancer.

Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan

J. Blay, K. Chan, T. Chen, 2022, Cancer.

Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma

H. Lien, K. Yeh, A. Cheng, 1999, American journal of hematology.

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2021, British Journal of Cancer.

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2018 .

Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.

M. Kudo, H. Shan, H. Lee, 2018 .

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

M. Kudo, A. Zhu, R. Finn, 2019, Journal of Clinical Oncology.

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

M. Kudo, T. Yau, R. Finn, 2020 .

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

P. Galle, R. Lencioni, M. Ducreux, 2021, Journal of Clinical Oncology.

FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization

Chiun Hsu, A. Cheng, D. Ou, 2019, Journal of Hepatology.

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

M. Kudo, A. Zhu, R. Finn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma

Chiun Hsu, Chih-Hung Hsu, A. Cheng, 2022, European Radiology.

A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

B. Sangro, Jeffrey Anderson, C. D. Cruz, 2016 .

G06 : A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

M. Kudo, N. Izumi, I. Sheen, 2015 .

RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).

M. Kudo, J. Bruix, J. Llovet, 2014 .

Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

H. Van Vlierberghe, C. Love, G. Abou-Alfa, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

P. Galle, R. Lencioni, A. Zhu, 2021 .

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

M. Kudo, E. Raymond, R. Finn, 2014 .

Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma

Chung-Wu Lin, A. Cheng, S. Kuo, 2010, Annals of Hematology.

Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response.

C. Tsai, Y. Pu, A. Cheng, 1996, The Journal of urology.

Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.

Y. Pu, A. Cheng, I. Su, 1996, British journal of urology.

Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy.

Chih-Hung Hsu, H. Hsu, P. Yeh, 2004, Anticancer research.

Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.

A. Cheng, 1996, Blood.

Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.

M. Hergenhahn, Chih-Hung Hsu, P. Yeh, 2002, Anticancer research.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

M. Kudo, A. Zhu, R. Finn, 2018, The Lancet. Oncology.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.

Chiun Hsu, J. Lee, A. Cheng, 2013, European journal of cancer.

Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2010, Cancer.

Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2008 .

Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.

K. Yeh, A. Cheng, 1994, Journal of the Formosan Medical Association = Taiwan yi zhi.

Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada.

A. Cheng, T. Decaens, J. Raoul, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation.

K. Yeh, P. Yeh, S. Chuang, 2002, Biochemical pharmacology.

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

M. Kudo, J. Furuse, G. Abou-Alfa, 2021, The Lancet. Oncology.

Establishment of a novel MALT lymphoma cell line, ma‐1, from a patient with t(14;18)(q32;q21)‐positive Helicobacter Pylori‐Independent Gastric MALT Lymphoma

K. Yeh, Chung-Wu Lin, A. Cheng, 2011, Genes, chromosomes & cancer.

Stability of curcumin in buffer solutions and characterization of its degradation products.

Jen-kun Lin, Y. Ho, Y. J. Wang, 1997, Journal of pharmaceutical and biomedical analysis.

Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.

Chiun Hsu, A. Cheng, Jia-Hong Chen, 2018, Journal of hepatology.

Weekly cisplatin plus infusional high‐dose 5‐fluorouracil and leucovorin (P‐HDFL) for metastatic urothelial carcinoma

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2006, Cancer.

Clinical studies with curcumin.

Chih-Hung Hsu, A. Cheng, 2007, Advances in experimental medicine and biology.

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

S. Jee, Y. Pu, A. Cheng, 2001, Anticancer research.

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

M. Kudo, J. Lee, S. Sarin, 2017, Hepatology International.

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Siyi Liu, 2012, British Journal of Cancer.

Clinicopathologic features and responses to radiotherapy of myeloid sarcoma

K. Lan, A. Cheng, S. Kuo, 2013, Radiation Oncology.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

M. Kudo, R. Finn, J. Jassem, 2018, The Lancet.

Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?

Y. C. Chen, A. Cheng, I. Su, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.

A. Cheng, Ying-Chun Shen, Tsung-Hao Liu, 2022, Journal of the Formosan Medical Association = Taiwan yi zhi.

Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence

R. Poon, A. Cheng, Li‐Chun Lu, 2014, Seminars in Liver Disease.

High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5‐fluorouracil‐based systemic chemotherapy

Po-Huang Lee, C. Shun, K. Yeh, 1998, Cancer.

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Jeong Min Lee, Masatoshi Kudo, Ryosuke Tateishi, 2010, Hepatology international.

Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.

Ding‐Shinn Chen, Chien-Hung Chen, Guan-Tarn Huang, 2009, European journal of cancer.

Treatment of Hepatocellular Carcinoma with Thalidomide: Assessment with Power Doppler Ultrasound

Chiung-Nien Chen, Chiun Hsu, A. Cheng, 2009 .

Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions.

H. Hsu, S. Chuang, A. Cheng, 2000, Experimental hematology.

Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis.

Jen-kun Lin, M. Kuo, Chih-Hung Hsu, 2000, Carcinogenesis.

A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial

C. Hsiung, Chiun Hsu, A. Cheng, 2008, Hepatology.

High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.

K. Yeh, A. Cheng, K. H. Yeh, 1997, British Journal of Cancer.

Synergistic effect of radiation and interleukin-6 on hepatitis B virus reactivation in liver through STAT3 signaling pathway.

Y. Jeng, J. Cheng, A. Cheng, 2009, International journal of radiation oncology, biology, physics.

Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells

Po-Huang Lee, H. Hsu, J. Cheng, 2007, Clinical Cancer Research.

Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients.

J. Whang‐Peng, C. Hsiung, C. Wen, 2005, World journal of gastroenterology.

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.

Chiun Hsu, J. Cheng, A. Cheng, 2004, Journal of the Formosan Medical Association = Taiwan yi zhi.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.

M. Wei, C. Teng, S. Pan, 2015, Cancer letters.

Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism.

S. Chuang, A. Cheng, G. Lai, 2013, Free radical biology & medicine.

Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

M. Kudo, E. Raymond, Yoon-Koo Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases

J. Shih, J. Yang, K. Lan, 2015, PloS one.

The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells

A. Cheng, J. Guh, L. Hsu, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma

Y. Jeng, H. Hsu, Chih-Hung Hsu, 2020 .

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.

M. Kudo, Chiun Hsu, S. Choo, 2020, Journal of hepatology.

A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

A. Cheng, Ching-Hung Lin, Bang-Bin Chen, 2016, BMC Cancer.

P53 overexpression predicts poor chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection

King-Jen Chang, H. Hsu, Yung-Ming Cheng, 2002, International journal of cancer.

Hypermethylation of the p16 Gene in Sporadic T3N0M0 Stage Colorectal Cancers: Association with DNA Replication Error and Shorter Survival

King-Jen Chang, H. Hsu, Yung-Ming Cheng, 1999, Oncology.

Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma.

K. Yeh, Chung-Wu Lin, P. Yeh, 2008, Blood.

Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death

K. Yeh, P. Yeh, S. Chuang, 2004, Oncogene.

The emerging epidemic of estrogen‐related cancers in young women in a developing Asian country

M. Lai, Chiun-Sheng Huang, S. You, 2012, International journal of cancer.

Epithelial Cells in Cystatin M AKT 1-Mediated Epigenetic Silencing of Associated Fibroblasts Confer − Breast Cancer

Michael C. Ostrowski, Daniel E. Deatherage, Shuying Sun, 2008 .

Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Kuen-Feng Chen, Chih-Hung Hsu, A. Cheng, 2011, Journal of Pharmacology and Experimental Therapeutics.

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Y. Jeng, A. Cheng, Shiu-Feng Huang, 2021, Liver Cancer.

Interleukin‐6 is responsible for drug resistance and anti‐apoptotic effects in prostatic cancer cells

M. Kuo, Y. Pu, S. Chuang, 2004, The Prostate.

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays

Chiun-Sheng Huang, W. Kuo, Chung‐Chieh Wang, 2015, Scientific Reports.

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3

Kuen-Feng Chen, A. Cheng, Chun-Yu Liu, 2011, Molecular Cancer Therapeutics.

Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-κB Activation by Protein Phosphatase 4-mediated NF-κB p65 Thr Dephosphorylation*

K. Yeh, P. Yeh, S. Chuang, 2004, Journal of Biological Chemistry.

Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells.

K. Yeh, P. Yeh, S. Chuang, 2003, Biochemical pharmacology.

Additional file 4: Figure S4.

A. Cheng, Ching-Hung Lin, Yen-Shen Lu, 2012 .

Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma

Kuen-Feng Chen, Yan-Hwa Wu Lee, A. Cheng, 2012, Molecular medicine.

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma

J. Cheng, A. Cheng, M. Gao, 2014, Oncotarget.

KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells

Yih-Leong Chang, K. Yeh, A. Cheng, 2012, PloS one.

Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma

J. Cheng, A. Cheng, K. Tzen, 2015, Journal of gastroenterology and hepatology.

Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer

Chen-Yang Shen, Chiun-Sheng Huang, I. Chen, 2016, Scientific Reports.

High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib

Chih-Hung Hsu, A. Cheng, Y. Shao, 2015, Clinical Cancer Research.

Transactivation of the human MDR1 gene by hepatitis B virus X gene product.

S. Chuang, A. Cheng, S. Doong, 1998, Journal of hepatology.

Increased Risk of Parvovirus B19 Infection in Young Adult Cancer Patients Receiving Multiple Courses of Chemotherapy

Yun-Ru Liu, A. Cheng, S. Kuo, 2002, Journal of Clinical Microbiology.

Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma

Chiun-Sheng Huang, I. Chen, H. Lien, 2023, Breast Cancer Research.

Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells

Y. Tsai, Y. Pu, J. Cheng, 2015, Molecular Cancer Therapeutics.

Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.

Chih-Hung Hsu, P. Yeh, A. Cheng, 2010, Cancer letters.

Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma

Chiun Hsu, A. Cheng, Pai-Sheng Chen, 2022, British Journal of Cancer.

Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan.

M. Lai, K. Yeh, Chih-Hung Hsu, 2015, Clinical colorectal cancer.

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

J. Bruix, J. Llovet, G. Meinhardt, 2017, Journal of hepatology.

Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.

Chih-Hung Hsu, Ting-Chun Kuo, Chiun Hsu, 2016, World journal of gastroenterology.

Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma

K. Yeh, A. Cheng, Y. Tien, 2021, Oncoimmunology.

Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management.

A. Cheng, I. Su, Chiu‐Hwa Wang, 1995, Leukemia & lymphoma.

Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.

C. Shun, K. Yeh, Chung-Wu Lin, 2017, Blood.

Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas.

Hsiu‐Po Wang, K. Yeh, Chung-Wu Lin, 2012, Blood.

Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012.

T. Yau, Yoon-Koo Kang, I. Tan, 2012, The Lancet. Oncology.

CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer

K. Yeh, A. Cheng, Jin-Tung Liang, 2018, Oncology.

Disseminated Peritoneal Leiomyomatosis Responds to Systemic Chemotherapy

C. Shun, A. Cheng, C. Hsu, 2008, Oncology.

Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer

King-Jen Chang, Y. Chien, W. Hwu, 2012, Journal of Human Genetics.

β-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2014, Oncology.

Lenalidomide as second‐line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy

A. Cheng, Y. Shao, D. Ou, 2017, Alimentary pharmacology & therapeutics.

Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy.

Chiun Hsu, Chih-Hung Hsu, A. Cheng, 2016, Radiology.

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

E. Raymond, J. Douillard, Jun Suk Kim, 2009, The Lancet. Oncology.

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.

Chi-Ying F. Huang, Y. Jeng, H. Hsu, 2009, Journal of hepatology.

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment

C. Shun, Chih-Hung Hsu, A. Cheng, 2018, Liver Cancer.

High‐frequency microsatellite instability predicts better chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection

King-Jen Chang, H. Hsu, Yung-Ming Cheng, 2002, International journal of cancer.

Primary central nervous system diffuse large B‐cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart

L. Medeiros, A. Cheng, Ching-Hung Lin, 2015, Histopathology.

Primary Central Nervous System Diffuse Large B-cell Lymphoma Has Poorer Immune Cell Infiltration and Prognosis than Peripheral Counterpart

L. Medeiros, A. Cheng, Ching-Hung Lin, 2015 .

Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.

H. Hsu, A. Cheng, K. Kuo, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma.

S. Yeh, M. Hu, A. Cheng, 2023, Cancer letters.

OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.

Kuen-Feng Chen, M. Kuo, Chih-Hung Hsu, 2008, Cancer research.

Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

K. Yeh, Chung-Wu Lin, A. Cheng, 2019, Cancers.

Effect of glucocorticoid use on survival in patients with stage I–III breast cancer

Chiun-Sheng Huang, S. You, A. Cheng, 2018, Breast Cancer Research and Treatment.

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

J. Yang, Chia‐Chi Lin, A. Cheng, 2019, Targeted Oncology.

Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

M. Kudo, S. Thongprasert, Yoon-Koo Kang, 2016, Hepatology.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

M. Kudo, A. Zhu, R. Finn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.

M. Kudo, N. Izumi, Yoon-Koo Kang, 2015, Journal of hepatology.

Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.

Kuen-Feng Chen, A. Cheng, Chun-Yu Liu, 2012, Biochemical pharmacology.

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

K. Yeh, A. Cheng, N. Chiang, 2015, Cancer Chemotherapy and Pharmacology.

Molecular targeted therapy for advanced hepatocellular carcinoma

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2007, Targeted Oncology.

Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.

Chiung-Nien Chen, Chiun Hsu, F. Hsieh, 2005, Radiology.

Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma

Chiung-Nien Chen, Chiun Hsu, Pei-Ming Yang, 2003, Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

P. Galle, R. Lencioni, T. Greten, 2021, Journal for ImmunoTherapy of Cancer.

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2021, Liver Cancer.

Primary thyroid lymphoma mimicking subacute thyroiditis.

A. Cheng, Tien-Chun Chang, Mu‐Zon Wu, 2006, Acta cytologica.

Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.

Y. Tsai, Y. Pu, J. Cheng, 2013, European journal of cancer.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

W. Pao, J. Shih, Yeun-Chung Chang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

Pan‐Chyr Yang, K. Yeh, A. Cheng, 1999, Cancer.

Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy

Chiun Hsu, A. Cheng, D. Ou, 2018, Seminars in Liver Disease.

Potential synergistic anti-tumor effects between sorafenib and the MEK inhibitor CI1040 in hepatocellular carcinoma (HCC)

Chiun Hsu, Sung-Liang Yu, A. Cheng, 2008 .

Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.

Yeun-Chung Chang, Pan‐Chyr Yang, Chih-Hung Hsu, 2008, Lung cancer.

Phase II trial combining paclitaxel with 24‐hour infusion cisplatin for chemotherapy‐naïve patients with locally advanced or metastatic breast carcinoma

Chiun-Sheng Huang, Chiun Hsu, A. Cheng, 2002, Cancer.

Clinicopathologic features and responses to radiotherapy of myeloid sarcoma

K. Lan, A. Cheng, S. Kuo, 2013, Radiation oncology.

Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.

Y. Tsai, Chih-Hung Hsu, Chao-yuan Huang, 2007, Urology.

Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy

Chiun-Sheng Huang, King-Jen Chang, H. Lien, 2010, Journal of Zhejiang University SCIENCE B.

Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia

Chiun-Sheng Huang, King-Jen Chang, A. Cheng, 2009, Cancer Epidemiology Biomarkers & Prevention.

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

M. Ducreux, G. Abou-Alfa, W. Fang, 2022, Liver Cancer.

Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy

Y. Jeng, Chien-Hung Chen, Chih-Hung Hsu, 2021, Cancers.

Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma

Chih-Hung Hsu, A. Cheng, Bang-Bin Chen, 2021, Diagnostics.

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2020, ESMO Open.

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

J. Furuse, G. Abou-Alfa, R. Finn, 2020, Journal of hepatology.

Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.

R. Kelley, T. Yau, L. Rimassa, 2020, Future oncology.

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

P. Chow, M. Kudo, H. Lee, 2020, Future oncology.

Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer

J. Shih, J. Yang, A. Cheng, 2018, Clinical and translational radiation oncology.

Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Chih-Hung Hsu, Y. Chao, C. Yen, 2019, Liver Cancer.

Clinical Outcome and Toxicity Predictors of Thoracic Re-irradiation for Locoregionally Recurrent Lung Cancer

J. Shih, A. Cheng, S. Kuo, 2018, International Journal of Radiation Oncology, Biology, Physics.

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

I. Chen, Li-Ping Hsiao, A. Cheng, 2017, Scientific Reports.

Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma.

M. Lai, J. Yang, A. Cheng, 2015, Clinical lung cancer.

Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

Chih-Hung Hsu, A. Cheng, Y. Shao, 2013, Liver Cancer.

A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

A. Cheng, Ching-Hung Lin, Bang-Bin Chen, 2016, BMC Cancer.

Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study

Y. Tsai, Chih-Hung Hsu, Chao-yuan Huang, 2007, Anti-cancer drugs.

EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.

J. Shih, Pan‐Chyr Yang, K. Yeh, 2009, Lung cancer.

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2010, Journal of Gastroenterology.

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice

M. Lai, J. Yang, A. Cheng, 2016, Journal of Cancer.

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy

K. Yeh, Jen-Chieh Lee, A. Cheng, 2017, PloS one.

H. Ueno, J. Furuse, Y. Ohashi, 2017, ESMO Open.

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

H. Ueno, J. Furuse, K. Mizumoto, 2017, Journal of Cancer Research and Clinical Oncology.

Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer

K. Yeh, A. Cheng, Y. Tien, 2016, Journal of gastroenterology and hepatology.

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

H. Ueno, J. Furuse, Y. Ohashi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

Chih-Hung Hsu, A. Cheng, Y. Tien, 2011, Oncology.

Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

M. Kudo, P. Galle, M. Ducreux, 2021, Journal of hepatology.

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

A. Gasbarrini, M. Kudo, J. Bruix, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Gisela Schwab, Tim Meyer, Stephen Lam Chan, 2018, The New England journal of medicine.

Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma

Chih-Hung Hsu, A. Cheng, Yong-Shi Li, 2019, Cancers.

Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas.

S. Chuang, A. Cheng, G. Lai, 2005, Human molecular genetics.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.

Chiun-Sheng Huang, Chiun Hsu, A. Cheng, 2010, Japanese journal of clinical oncology.

Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

Chiun Hsu, Y. Chao, A. Cheng, 2012, Journal of hepatology.

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia.

Ming-Tseh Lin, S. Chuang, A. Cheng, 2008, Cancer letters.

Expression of P‐glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation

H. Hsu, A. Cheng, A. Cheng, 1997, Journal of gastroenterology and hepatology.

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

T. Yau, Haitao Zhao, A. Cheng, 2021, Liver Cancer.

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma

Chih-Hung Hsu, A. Cheng, Yi‐Hsiang Huang, 2021, Journal of hepatocellular carcinoma.

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

M. Kudo, S. Choo, S. Ye, 2020, Liver Cancer.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.

Yoon-Koo Kang, Jianming Xu, Jun Suk Kim, 2012, European journal of cancer.

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach.

Chiun Hsu, A. Cheng, Li‐Tzong Chen, 2010, Journal of hepatology.

Direct cardiac effects of As2O3 in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration.

A. Cheng, Mei-Hwan Wu, M. Su, 2003, Toxicology and applied pharmacology.

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

M. Kudo, R. Finn, F. Piscaglia, 2021, Journal of Gastroenterology.

Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1–2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy

Chiun-Sheng Huang, H. Lien, W. Kuo, 2016, Annals of Surgical Oncology.

Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges

Chiun Hsu, Chih-Hung Hsu, A. Cheng, 2016, Liver Cancer.

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?

Chih-Hung Hsu, A. Cheng, Y. Shao, 2015, World journal of gastroenterology.

Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma

K. Yeh, Chung-Wu Lin, A. Cheng, 2022, Cancers.

Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab

Chung-Wu Lin, A. Cheng, S. Kuo, 2013, Annals of Hematology.

M. Kudo, A. Zhu, R. Finn, 2020, Cancer.

HER‐2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti‐HER‐2/neu regulation of cell growth and chemosensitivity

H. Hsu, Chiun Hsu, Po-Huang Lee, 2002, Cancer.

Revisiting the Full Spectrum of Helicobacter pylori -Related Gastric Lymphoma

K. Yeh, Chung-Wu Lin, A. Cheng, 2021 .

Helicobacter pylori and mucosa-associated lymphoid tissue: what's new.

A. Cheng, S. Kuo, 2013, Hematology. American Society of Hematology. Education Program.

Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.

J. J. Tai, J. Whang‐Peng, Hsiu‐Po Wang, 2005, Journal of the National Cancer Institute.

Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation

Chiun-Sheng Huang, Chung‐Chieh Wang, A. Cheng, 2012, Journal of Clinical Pathology.

Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy

A. Cheng, Ching-Hung Lin, Yen-Shen Lu, 2012, BMC Cancer.

Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas

J. Shih, J. Yang, A. Cheng, 2013, Journal of Neuro-Oncology.

CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.

Kuen-Feng Chen, A. Cheng, Ching‐Chow Chen, 2012, Oral oncology.

Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, A. El-Khoueiry, T. Meyer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, A. El-Khoueiry, T. Yau, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A Single-Arm Phase Ib/II Study of Lenvatinib Plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.

T. Chen, Jen-Chieh Lee, A. Cheng, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma

A. Cheng, P. Hsu, D. Ou, 2018, Liver Cancer.

Abstract P3-14-18: Result of Phase I Part of a Phase I/II Study of Lapatinib (L) Plus Oral Vinorelbine (oVNR) in Metastatic Breast Cancer (MBC) Patients Overexpressing ErbB2

A. Cheng, C. Huang, Y-C Shen, 2010 .

Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors.

H. Lien, K. Yeh, M. Kuo, 2005, World journal of gastroenterology.

Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells.

P. Yeh, S. Chuang, A. Cheng, 2002, Biochemical pharmacology.

Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway*

H. Hsieh, Kuen-Feng Chen, Chiun Hsu, 2009, Journal of Biological Chemistry.

Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study.

M. Lai, Chiun-Sheng Huang, S. You, 2014, The oncologist.

Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort

K. Yeh, A. Cheng, Jin-Tung Liang, 2021, British Journal of Cancer.

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

K. Yeh, C. Yen, A. Cheng, 2014, British Journal of Cancer.

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

M. Kudo, H. Van Vlierberghe, A. Zhu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.

Kuen-Feng Chen, K. Yeh, P. Yeh, 2008, Cancer research.

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages

A. Cheng, Muh-Hwa Yang, D. Ou, 2021, Journal for ImmunoTherapy of Cancer.

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.

Kuen-Feng Chen, A. Cheng, Shoei‐Sheng Lee, 2010, Journal of hepatology.

Prognostic factors in extrapulmonary small cell carcinomas. A large retrospective study.

A. Cheng, K. Kuo, S. Kuo, 2007, Oncology.

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT].

R. Finn, F. Piscaglia, L. Wyrwicz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

5097 Poor response to systemic chemotherapy in metaplastic carcinoma of breast

Yiling Lu, I. Chen, A. Cheng, 2009 .

Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors.

Y. C. Chen, A. Cheng, I. Su, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

Chiun-Sheng Huang, Ching-Hung Lin, Tiffany Ting-Fang Shih, 2015, Clinical Cancer Research.

Targeting tumor‐infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Yao-Hsu Yang, 2018, International journal of cancer.

Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer

Yih-Leong Chang, Chen‐Tu Wu, K. Lan, 2018, Radiation Oncology.

Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma

Ding‐Shinn Chen, K. Yeh, S. Chuang, 1996, Cancer.

Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicin.

Yan Song, K. Yeh, P. Yeh, 2001, Biochemical and biophysical research communications.

A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women.

Chiun-Sheng Huang, W. Kuo, A. Cheng, 2020, Environment international.

No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen

M. Lai, Chiun-Sheng Huang, T. Chen, 2014, Breast Cancer Research and Treatment.

AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation

A. Cheng, S. Kuo, Li‐Tzong Chen, 2015, Leukemia & lymphoma.

A Patient with refractory metastatic germ cell tumor successful salvaged after treatment with paclitaxel, ifosfamide, and high-dose 5-Fluorouracil infusional therapy

A. Cheng, K. Chiang, 2019, Journal of Cancer Research and Practice.

Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas.

Hsiu‐Po Wang, K. Yeh, Chung-Wu Lin, 2021, Journal of the Formosan Medical Association = Taiwan yi zhi.

First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma

Hsiu‐Po Wang, M. Wei, K. Yeh, 2017, Scientific Reports.

Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer

K. Yeh, A. Cheng, Y. Shao, 2017, Supportive Care in Cancer.

CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer

Chiun-Sheng Huang, H. Lien, A. Cheng, 2013, BioMed research international.

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

I. Chen, A. Cheng, Ching-Hung Lin, 2021, Breast.

Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity

Hsiu‐Po Wang, K. Yeh, A. Cheng, 2014, Blood Cancer Journal.

Reliability of a Single-region Sample to evaluate Immune Tumor Microenvironment in Hepatocellular Carcinoma.

M. Ho, Y. Jeng, A. Cheng, 2020, Journal of hepatology.

Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma.

Chih-Hung Hsu, Y. Pu, Chia‐Chi Lin, 2008, Urologic oncology.

A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.

Chih-Hung Hsu, Y. Chao, A. Cheng, 2020, The oncologist.

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

Chih-Hung Hsu, Chia‐Chi Lin, A. Cheng, 2006, Investigational New Drugs.

Liver Cancer Working Group report.

B. Choi, M. Kudo, J. Furuse, 2010, Japanese journal of clinical oncology.

Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki‐1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13‐Cis retinoic acid

D. Liang, A. Cheng, I. Su, 1996, Cancer.

Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design.

Chiun Hsu, A. Cheng, F. Hu, 2010, Contemporary clinical trials.

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer

K. Yeh, A. Cheng, J. F. Lin, 2005, British Journal of Cancer.

A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer

T. Chen, A. Cheng, Ching-Hung Lin, 2018, Japanese journal of clinical oncology.

Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation.

C. Huang, K. Yeh, A. Cheng, 2010, Anticancer research.

Minimal Toxicity to Myeloid Progenitor Cells of Weekly24‐Hr Infusion of High‐Dose 5‐Fluorouracil: Direct Evidence from Colony Forming Unit‐Granulocyte andMonocyte (CFU‐GM) Clonogenic Assay

K. Yeh, S. Yeh, A. Cheng, 2000 .

Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay.

K. Yeh, S. Yeh, A. Cheng, 2000, Pharmacology & toxicology.

Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24‐hour infusion of high‐dose 5‐fluorouracil and leucovorin

K. Yeh, A. Cheng, 1998, British journal of haematology.

Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer

Hsiu‐Po Wang, I. Lai, Ming-Tsan Lin, 2015, PloS one.

Erratum to: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

Chiun Hsu, K. Yeh, A. Cheng, 2012, Gastric Cancer.

Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation.

K. Yeh, Chih-Hung Hsu, A. Cheng, 2008, Anticancer research.

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract

K. Yeh, A. Cheng, C. Hsu, 2004, British Journal of Cancer.

An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer

K. Yeh, W. Su, Y. Chao, 2006, British Journal of Cancer.

An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin.

K. Yeh, A. Cheng, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

Chiun Hsu, K. Yeh, A. Cheng, 2011, Gastric Cancer.

Differential expression of glucocorticoid receptor in carcinomas of the human digestive system

H. Lien, A. Cheng, C. Shun, 2008, Histopathology.

STAT3 Mediated Inhibition of - in Hepatocellular Carcinoma through SHP-1 Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance

A. Cheng, C. Shiau, W. Tai, 2014 .

Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

E. Raymond, S. Faivre, A. Cheng, 2018, Hepatology.

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

S. Kulp, Dasheng Wang, A. Cheng, 2007, Hepatology.

Early Gastric Cancer as a Possible Cause of Cauda Equina Syndrome and Disseminated Intravascular Coagulation

J. Wong, A. Cheng, Cheng-Yi Wang, 1997 .

Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer.

K. Yeh, Chih-Hung Hsu, A. Cheng, 2012, Anticancer research.

Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma

Chiun Hsu, Chih-Hung Hsu, A. Cheng, 2017, European Radiology.

Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma

A. Zhu, A. Cheng, Ying-Chun Shen, 2012, Oncology.

Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity

J. Cheng, A. Cheng, Wan-Ni Yu, 2023, Journal of clinical and translational hepatology.

Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior

Wei-Ting Huang, Chung-Wu Lin, A. Cheng, 2014, Modern Pathology.

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

Ym Chen, A. Cheng, P-C. Yang, 2002, British Journal of Cancer.

Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women

C. Hudis, I. Chen, A. Dannenberg, 2017, Cancer Prevention Research.

Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy

Chiun Hsu, A. Cheng, Shu‐Chen Wei, 2009, Hepatology.

Angioimmunoblastic lymphadenopathy with dysproteinemia--lack of a prognostic value of clear cell morphology.

Y. C. Chen, A. Cheng, I. Chiang, 1997, Oncology.

IκB kinases increase Myc protein stability and enhance progression of breast cancer cells

P. Yeh, A. Cheng, Yen-Shen Lu, 2011, Molecular Cancer.

Primary squamous cell carcinoma of the thyroid with cardiac metastases and right ventricle outflow tract obstruction.

A. Cheng, Kuo-Hsing Chen, Y. Chou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression

Chiun Hsu, Chiun Hsu, A. Cheng, 2012, Oncology.

Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

M. Lai, K. Yeh, A. Cheng, 2016, BMC Cancer.

Pre-clinical and early-phase clinical studies of curcumin as chemopreventive agent for endemic cancers in Taiwan.

Jen-kun Lin, M. Hergenhahn, M. Kuo, 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

M. Kudo, G. Poggi, E. Raymond, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Considerations of heterogeneity in clinical trials for hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2019, Expert review of gastroenterology & hepatology.

Type 2 diabetes mellitus is associated with increased mortality in Chinese patients receiving curative surgery for colon cancer.

M. Lai, K. Yeh, A. Cheng, 2014, The oncologist.

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

M. Kudo, A. Zhu, R. Finn, 2022, European journal of cancer.

Re‐evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel

M. Kudo, J. Geschwind, D. Amarapurkar, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Retinoic acid‐induced apoptosis and regression of a refractory Epstein‐Barr virus‐containing T cell lymphoma expressing multidrug‐resistance phenotypes

A. Cheng, I. Su, J. Lay, 1993, British journal of haematology.

Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study

M. Kudo, A. Zhu, R. Finn, 2016 .

Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis.

I. Chen, A. Cheng, Ching-Hung Lin, 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.

The impact of diabetes mellitus on prognosis of early breast cancer in Asia.

M. Lai, A. Cheng, Yen-Shen Lu, 2012, The oncologist.

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2022, BMC Cancer.

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

M. Kudo, N. Izumi, I. Sheen, 2018, The lancet. Gastroenterology & hepatology.

A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.

Y. Tsai, Chih-Hung Hsu, Y. Chiang, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

M. Kudo, P. Galle, R. Lencioni, 2022, Liver Cancer.

OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

M. Kudo, H. Lee, A. Cheng, 2014 .

FRI-494-Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis

M. Kudo, H. Lee, A. Cheng, 2019, Journal of Hepatology.

Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS

M. Kudo, H. Lee, A. Cheng, 2018 .

Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE.

M. Kudo, H. Lee, A. Cheng, 2018 .

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

T. Meyer, C. Yen, A. Cheng, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.

Chih-Hung Hsu, A. Cheng, Y. Shao, 2010, Journal of Hepatology.

Sorafenib for the treatment of hepatocellular carcinoma across geographic regions

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2009, Expert review of clinical pharmacology.

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)

M. Kudo, D. Amarapurkar, H. Lee, 2013, Liver international : official journal of the International Association for the Study of the Liver.

Perspectives on the Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy

Chiun Hsu, S. Morita, A. Cheng, 2012, Liver Cancer.

Antiangiogenic strategies for the treatment of hepatocellular carcinoma

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2011 .

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

K. Rau, Tae-You Kim, Joong-Won Park, 2021, British Journal of Cancer.

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

M. Kudo, A. Zhu, G. Abou-Alfa, 2016 .

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

A. Cheng, H. Toh, C. Hsu, 2010, British Journal of Cancer.

1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240

M. Kudo, A. Zhu, R. Finn, 2020 .

Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe

T. Murakami, M. Kudo, Y. Minami, 2015, Liver Cancer.

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia

Jin Wook Chung, P. Chow, S. Ye, 2011, Oncology.

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007, Urologic oncology.

Original article Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007 .

Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases

A. Cheng, P. Liang, Y. Shao, 2013, International journal of hepatology.

Evolution of systemic treatment for advanced hepatocellular carcinoma

A. Cheng, Ying-Chun Shen, Tsung-Che Wu, 2021, The Kaohsiung journal of medical sciences.

High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia

R. Huang, J. Thiery, Chiun-Sheng Huang, 2021, npj Breast Cancer.

High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia

R. Huang, J. Thiery, Chiun-Sheng Huang, 2021, NPJ breast cancer.

A Pathway for Tumor Necrosis Factor-α-induced Bcl10 Nuclear Translocation

K. Yeh, Chih-Hung Hsu, P. Yeh, 2006, Journal of Biological Chemistry.

Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian versus Western Populations.

Chiun-Sheng Huang, I. Chen, W. Kuo, 2019, The oncologist.

NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells.

M. Kuo, P. Yeh, A. Cheng, 2008, Biochemical and biophysical research communications.

Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

A. Zhu, R. Kelley, A. El-Khoueiry, 2019, Annals of Oncology.

Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome

Kuen-Feng Chen, A. Cheng, Chun-Yu Liu, 2013, PloS one.

First‐line antibiotic treatment in patients with localized extragastric mucosa‐associated lymphoid tissue lymphoma

Chung-Wu Lin, A. Cheng, S. Kuo, 2022, EJHaem.

A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue

J. J. Tai, C. Ko, Hsiu‐Po Wang, 2019, Haematologica.

Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma

Chiun Hsu, Chih-Hung Hsu, A. Cheng, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

Mohamed Bouattour, Xun Lin, Yoon-Koo Kang, 2011, Clinical Cancer Research.

t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement

K. Yeh, Chung-Wu Lin, Chih-Hung Hsu, 2011, Cancer Chemotherapy and Pharmacology.

IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

M. Ducreux, A. Cheng, S. Qin, 2021, Zeitschrift für Gastroenterologie.

Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC

P. Galle, M. Ducreux, A. Zhu, 2021, Clinical Trials.

Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).

M. Kudo, P. Galle, M. Ducreux, 2020 .

E. Raymond, J. Douillard, Jun Suk Kim, 2011, Journal of Translational Medicine.

Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.

S. Chuang, A. Cheng, G. Lai, 2007, Cancer research.

Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis

Chiun Hsu, A. Cheng, C. Chiu, 2005, Cancer Epidemiology Biomarkers & Prevention.

Phosphatidylinositol 3-Kinase/Akt Pathway Cells in Part through the Inhibition of the Resistance in Hepatocellular Carcinoma Factor-related Apoptosis-inducing Ligand Bortezomib Overcomes Tumor Necrosis Mechanisms of Signal Transduction:

Kuen-Feng Chen, Chiun Hsu, Chih-Hung Hsu, 2014 .

A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma.

Yuh-Min Chen, R. Perng, Chun-Ming Tsai, 2007, Lung cancer.

Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma.

S. Kulp, J. Cheng, A. Cheng, 2012, International journal of radiation oncology, biology, physics.

Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma

K. Yeh, Y. Tsai, Chih-Hung Hsu, 2007, Anti-cancer drugs.

National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients.

M. Lai, Chih-Hung Hsu, A. Cheng, 2017, The oncologist.

Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer

T. Hwang, J. Whang‐Peng, Hsiu‐Po Wang, 2009, Cancer Chemotherapy and Pharmacology.

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.

J. Shih, Chiun Hsu, Pan‐Chyr Yang, 2008, Lung cancer.

Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer.

G. Ku, A. Cheng, G. Lopes, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma

S. Shyue, Chiun Hsu, A. Cheng, 2015, Oncotarget.

No evidence of IGH‐MALT1‐translocation in the Ma‐1 cell line–A reply

K. Yeh, A. Cheng, S. Kuo, 2013, Genes, Chromosomes and Cancer.

Beware imposters: MA‐1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B‐cell lymphoma cell line—A reply: Despite the same 8‐code STR, MA‐1 and Pfeiffer are cytogenetically diverse

K. Yeh, A. Cheng, C. Li, 2014, Genes, chromosomes & cancer.

Weekly CAF chemotherapy for advanced breast cancer patients.

J. Whang‐Peng, C. Hsiung, A. Cheng, 1997, Oncology.

Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer

Yih-Leong Chang, Chen‐Tu Wu, K. Lan, 2018, Radiation oncology.

Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer

Chiun Hsu, K. Yeh, W. Su, 2014, Oncology.

Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2022, Oncology.

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48‐h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

J. Whang‐Peng, Chiun Hsu, Hsiu‐Po Wang, 2006, Journal of gastroenterology and hepatology.

Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.

K. Yeh, Chih-Hung Hsu, Chia‐Chi Lin, 2013, Anticancer research.

Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin.

K. Yeh, Chih-Hung Hsu, A. Cheng, 1997, Anticancer research.

Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study.

A. Cheng, Ching-Hung Lin, Bang-Bin Chen, 2012 .

Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma: Need for a Revisit of Surgical Treatment

Hsiu‐Po Wang, K. Yeh, Chung-Wu Lin, 2008, Annals of surgery.

Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.

A. Zhu, T. Yau, R. Finn, 2021 .

Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

Yoon-Koo Kang, C. Shun, W. Su, 2013, Oncology.

Comparison of MALT and non‐MALT primary large cell lymphoma of the stomach

A. Cheng, Chiang‐Shin Liu, C. Hsu, 2001, Cancer.

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

M. Kudo, R. Finn, F. Piscaglia, 2019, British Journal of Cancer.

Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma.

M. Lai, Chih-Hung Hsu, A. Cheng, 2012, The oncologist.

Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma

J. Whang‐Peng, Chiun Hsu, A. Cheng, 2010 .

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

A. Cheng, K-F Chen, C-Y Liu, 2010, Oncogene.

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

M. Kudo, R. Finn, F. Piscaglia, 2021, Clinical Cancer Research.

Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.

Y. Tsai, Chih-Hung Hsu, Chao-yuan Huang, 2009, International journal of radiation oncology, biology, physics.

Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, A. El-Khoueiry, T. Meyer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The first two lines of chemotherapy for anthracycline-naïve metastatic breast cancer: A comparative study of efficacy between anthracyclines and nonanthracyclines.

Chiun Hsu, A. Cheng, Ching-Hung Lin, 2012 .

Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

A. Cheng, C. Hsu, Y-C Shen, 2004, British Journal of Cancer.

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

K. Yeh, Chih-Hung Hsu, A. Cheng, 2004, Hepato-gastroenterology.

Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.

A. Cheng, M. Chen, C. Hsu, 2000, Anticancer Research.

Tax of the human T-lymphotropic virus type I transactivates promoter of the MDR-1 gene.

S. Chuang, A. Cheng, M. Lin, 1997, Biochemical and biophysical research communications.

Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040

J. Furuse, G. Abou-Alfa, T. Yau, 2019, Annals of Oncology.

Phase I–II trial of weekly gemcitabine plus high‐dose 5‐fluorouracil and leucovorin in advanced pancreatic cancer

J. Whang‐Peng, Chih-Hung Hsu, Y. Chao, 2006, Journal of gastroenterology and hepatology.

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

M. Kudo, M. Kurosaki, T. Yau, 2021, Liver Cancer.

High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung.

K. Yeh, A. Cheng, 1997, Anticancer Research.

Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application

A. Cheng, S. Kuo, J. Lee, 2009, The British journal of dermatology.

Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Chih-Hung Hsu, Kuan-Der Lee, A. Cheng, 2012, Oncology.

Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040

J. Furuse, G. Abou-Alfa, R. Finn, 2019, Clinical research.

Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2019, Journal of Clinical Oncology.

Effect of national policy changes on hospice utilization and the invasiveness of end-of-life care in cancer patients.

M. Lai, Chih-Hung Hsu, A. Cheng, 2016 .

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer

I. Chen, T. Chen, Wen-Shuo Hsiao, 2023, Breast Cancer Research and Treatment.

Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).

M. Kudo, K. Rau, R. Finn, 2019, Journal of Clinical Oncology.

Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy.

Chih-Hung Hsu, A. Cheng, R. Hong, 2012, The oncologist.

Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.

K. Yeh, S. Yeh, A. Cheng, 2005, Anti-cancer drugs.

Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)

T. Murakami, M. Ho, Chiun Hsu, 2015, Liver Cancer.

Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma

A. Cheng, H. Hou, Chang-Tsu Yuan, 2022, Virchows Archiv.

Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.

Ding‐Shinn Chen, R. Fine, K. Yeh, 1998, Hepato-gastroenterology.

Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy

K. Rau, I. Chen, T. Chen, 2023, Journal of Cancer Research and Practice.

Polyprenoic acid in hepatocellular carcinoma.

A. Cheng, C. Yang, 1996, The New England journal of medicine.

Expression of BCL10 in cervical cancer has a role in the regulation of cell growth through the activation of NF-κB-dependent cyclin D1 signaling.

A. Cheng, S. Kuo, C. Chou, 2012, Gynecologic oncology.

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

M. Kudo, A. Zhu, R. Finn, 2017 .

Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.

Jang-Ming Lee, Hsiu‐Po Wang, K. Yeh, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

Young patients with colorectal cancer have increased risk of second primary cancers.

M. Lai, K. Yeh, A. Cheng, 2015, Japanese journal of clinical oncology.

1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation

M. Kudo, A. Zhu, T. Yau, 2020, Annals of Oncology.

Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size

M. Lai, J. Yang, Chih-Hung Hsu, 2013, PloS one.

Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity

M. Kuo, S. Chuang, A. Cheng, 1998, Oncogene.

Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study

N. Freemantle, G. Abou-Alfa, A. Cheng, 2019, Annals of Oncology.

Abstract 3725: Combined cytotoxic effects of volasertib and cisplatin in urothelial carcinoma cells

Chia-Chi Lin, Yu-Chieh Tsai, J. Yang, 2012 .

Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue: clinicopathologic analysis of 19 cases.

A. Cheng, I. Chiang, I. Su, 1996, Journal of the Formosan Medical Association = Taiwan yi zhi.

Abstract 2984: Normalization of tumor vasculature by anti-angiogenesis therapy in metastatic tumor: A clinical study to determine the timing and effect

A. Cheng, Ching-Hung Lin, Bang-Bin Chen, 2014 .

Activation of PI 3 K / Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Kuen-Feng Chen, Chih-Hung Hsu, A. Cheng, 2011 .

The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells

A. Cheng, J. Guh, L. Hsu, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

N. Strelkowa, J. Yang, Chih-Hung Hsu, 2020, British Journal of Cancer.

Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma

M. Lai, Chih-Hung Hsu, A. Cheng, 2013, Cancer.

Tumor compactness improves the preoperative volumetry-based prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy

Chia-Chun Kuo, Yu-Hsuan Chen, K. Lan, 2016, Oncotarget.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

A. Gasbarrini, W. Li, H. Harputluoglu, 2023, The Lancet.

Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): Initial results from the East/South East (E/SE) Asian subgroup

Keunchil Park, Yi-long Wu, H. Kuo, 2007 .

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab

P. Galle, M. Ducreux, A. Zhu, 2022, Liver Cancer.

Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials

Chih-Hung Hsu, A. Cheng, Bang-Bin Chen, 2021, Cancers.

Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials

Chih-Hung Hsu, A. Cheng, W. Shau, 2015, Oncology.

High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy

Chiun Hsu, Chih-Hung Hsu, A. Cheng, 2011, Oncology.

Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.

Kuen-Feng Chen, Chiun Hsu, Sung-Liang Yu, 2010, Cancer research.

Abstract CT284: Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation

M. Kudo, A. Zhu, T. Yau, 2020 .

1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC

M. Kudo, P. Galle, M. Ducreux, 2020 .

Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

M. Ho, Y. Ni, Chien-Hung Chen, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.

P. Galle, M. Ducreux, A. Zhu, 2018 .

Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age

Y. Jeng, A. Cheng, J. T. Liang, 2003, The British journal of surgery.

Relapse Pattern and Treatment Outcome of Curative Radiotherapy for Primary Cutaneous CD30+ Anaplastic Large-cell Lymphoma: A Retrospective Cohort Study.

A. Cheng, S. Kuo, Ji-Hong Hong, 2016, Acta dermato-venereologica.

M. Kudo, A. Zhu, R. Finn, 2019, Annals of Oncology.

A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment

J. Whang‐Peng, A. Cheng, T. Chao, 2016, Journal of Biomedical Science.

Recent advances in the treatment of metastatic colorectal cancer in Taiwan.

K. Yeh, A. Cheng, Yu-Lin Lin, 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib.

T. Meyer, C. Yen, A. Cheng, 2016 .

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

S. Larson, L. Schwartz, G. Abou-Alfa, 2017, Cancer Chemotherapy and Pharmacology.

Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling

Y. Tsai, Y. Pu, J. Cheng, 2023, British Journal of Cancer.

Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150.

R. Finn, A. Cheng, S. Qin, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

M. Kudo, A. Zhu, R. Finn, 2017 .

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.

M. Kudo, A. Zhu, R. Finn, 2017 .

Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).

L. Schwartz, G. Abou-Alfa, L. Saltz, 2014 .

Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large‐cell lymphoma of the stomach

Chiun Hsu, A. Cheng, I. Chiang, 2000, American journal of hematology.

Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer.

Yih-Leong Chang, K. Yeh, A. Cheng, 2013, Translational oncology.

M. Ho, Chih-Hung Hsu, A. Cheng, 2012, Anticancer Research.

Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems

A. Cheng, C. Hsu, Y. Shao, 2012, British Journal of Cancer.

The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia.

M. Lai, Chiun Hsu, J. Yang, 2015, The oncologist.

Clinical Activity of Metronomic Chemotherapy in Liver Cancers

Chih-Hung Hsu, A. Cheng, Y. Shao, 2014 .

Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).

M. Kudo, S. Thongprasert, Yoon-Koo Kang, 2015 .

Y. Tsai, Y. Pu, J. Cheng, 2013, European Journal of Cancer.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

M. Kudo, J. Bruix, J. Llovet, 2017, The Lancet.

Liver Cancer Working Group report.

B. Choi, M. Kudo, J. Furuse, 2010, Japanese Journal of Clinical Oncology.

Klotho‐beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma

Y. Jeng, H. Hsu, Chiun Hsu, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A

Kuen-Feng Chen, A. Cheng, Chun-Yu Liu, 2011, Molecular Cancer Therapeutics.

P-544 Final results of a phase I study with navelbine (NVB) oral in combination with cisplatin (C), evaluating two different schedules in advanced non-small cell lung cancer (NSCLC) patients

Yuh-Min Chen, R. Perng, Pan‐Chyr Yang, 2003 .

A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial

C. Hsiung, Chiun Hsu, A. Cheng, 2008, Hepatology.

Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients

A. Cheng, Jang-Yang Chang, H. Shiah, 2008 .

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3

Kuen-Feng Chen, A. Cheng, Chun-Yu Liu, 2011, Molecular Cancer Therapeutics.

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.

Kuen-Feng Chen, K. Yeh, P. Yeh, 2008, Cancer research.

Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Y. Shao, 2010, Cancer.

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients

Yih-Leong Chang, K. Yeh, A. Cheng, 2014, PloS one.

Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma

S. Shyue, Chiun Hsu, A. Cheng, 2015, Oncotarget.

Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma

Kuen-Feng Chen, Yan-Hwa Wu Lee, A. Cheng, 2012, Molecular medicine.

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

J. Bruix, J. Llovet, G. Meinhardt, 2017, Journal of hepatology.

KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

M. Kudo, A. Zhu, R. Finn, 2018 .

Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells.

T. Huang, A. Cheng, Ching-Hung Lin, 2011, Carcinogenesis.

OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.

Kuen-Feng Chen, M. Kuo, Chih-Hung Hsu, 2008, Cancer research.

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

Chih-Hung Hsu, A. Cheng, Y. Shao, 2014, Journal of hepatocellular carcinoma.

Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma

Chung-Wu Lin, A. Cheng, S. Kuo, 2017, Journal of radiation research.

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.

Chih-Hung Hsu, A. Cheng, Y. Shao, 2010, Journal of hepatology.

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)

M. Kudo, D. Amarapurkar, H. Lee, 2013, Liver international : official journal of the International Association for the Study of the Liver.

The emerging epidemic of estrogen‐related cancers in young women in a developing Asian country

M. Lai, Chiun-Sheng Huang, S. You, 2012, International journal of cancer.

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

I. Chen, Li-Ping Hsiao, A. Cheng, 2017, Scientific Reports.

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia

P. Chow, S. Ye, Joong-Won Park, 2011, Oncology.

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

A. Cheng, Y. Kwong, S. Kim, 2012, Leukemia & lymphoma.

K. Yeh, Chung-Wu Lin, P. Yeh, 2008, Blood.

Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?

Chiun-Sheng Huang, King-Jen Chang, S. You, 2011, Journal of Clinical Pathology.

O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.

A. Cheng, K. Kuo, Ching-Hung Lin, 2010, Lung cancer.

Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy.

Chiun Hsu, A. Cheng, Y. Shao, 2010 .

Cancer esearch apeutics , Targets , and Chemical Biology ction of DNA Damage-Inducible Gene GADD 45 β tributes to Sorafenib-Induced Apoptosis in R atocellular Carcinoma Cells

Kuen-Feng Chen, Chiun Hsu, Sung-Liang Yu, 2010 .

Sorafenib for the treatment of hepatocellular carcinoma across geographic regions

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2009, Expert review of clinical pharmacology.

Hypofractionated particle beam therapy for hepatocellular carcinoma–a brief review of clinical effectiveness

A. Cheng, S. Kuo, Chun-Wei Wang, 2019, World journal of gastrointestinal oncology.

Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.

Kuen-Feng Chen, Chao-yuan Huang, A. Cheng, 2013, International journal of radiation oncology, biology, physics.

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

M. Kudo, R. Finn, T. Yau, 2023, Liver Cancer.

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

M. Kudo, H. Lee, A. Cheng, 2023, Journal of Clinical Oncology.

213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors

J. Yang, A. Ohtsu, A. Cheng, 2014 .